Recombinant Human Kallikrein-13 (KLK13)

1. Relatively high levels of KLK13 expression in ESCC were associated with cell proliferation and correlated with tumor progression, advanced cancer stage, and poor prognosis PMID:29582368
2. Decreased KLK13 mRNA levels correlate with poor survival in esophageal squamous cell carcinoma patients. PMID:29221724
3. There was no significant association of KLK13 and KLK14 mRNA expression with the clinical factors ascitic fluid volume or residual tumor mass. In univariate Cox regression analysis, elevated KLK13 mRNA levels were significantly linked with shorter progression-free (PFS; hazard ratio [HR] = 1.97, P = 0.020) and overall survival (OS; HR = 1.81, P = 0.041). PMID:29546479
4. This first clinical study of KLK13 in bladder cancer reveals its deregulated expression in bladder tumors and highlights KLK13 as a promising marker for improving TaT1 patients' prognosis following treatment. PMID:27858162
5. Our results suggest that KLK13 mRNA expression constitutes a novel biomarker for the prediction of overall survival in nonsmall cell lung cancer and that its quantitative assessment in tumor tissues can aid in treatment decision making. PMID:25677900
6. KLK13 may play an important role in regulating cellular migration and invasiveness, making the loss of KLK13 a potential biomarker for early detection of lymph node metastasis in oral squamous cell carcinomas. PMID:23371469
7. Data indicate that five out of 9 SNPs in the KLK13 gene were associated with prostate cancer risk and/or aggressiveness. PMID:21741862
8. High KLK13 expression is associated with drug response in gastric cancer. PMID:22948777
9. Results indicate that KLK13 may play a role in the defense of the upper digestive apparatus and in male reproductive organs. PMID:21689719
10. Serine protease of Kazal-type (SPINK6) expressed in normal human skin is a potent natural inhibitor of Kallikrein-related peptidases, KLK12 and KLK13. PMID:21439340
11. these results reveal the enhancing effects of KLK13 on tumor cell invasion and migration, and that it may serve as a diagnostic/prognostic marker and a potential therapeutic target for lung cancer. PMID:21596022
12. This is the first study disclosing the possible clinical utility of KLK13 as a new tumor biomarker capable of predicting a favorable outcome for gastric cancer patients. PMID:20678496
13. KLK13 expression is an independent favorable prognostic marker for breast carcinoma PMID:11986781
14. kallikrein 13 is expressed in the nonmalignant and malignant prostate, with cancer tissues demonstrating slightly lower expression PMID:12970725
15. hK13 interacts and forms complexes with serum protease inhibitors, including alpha2-macroglobulin, alpha1-antichymotrypsin and alpha2-antiplasmin PMID:14687906
16. Human kallikrein13 may play a role in tissue remodeling and/or tumor invasion and metastasis. PMID:15381110
17. hK13 is expressed in several common salivary gland tumors PMID:16847813
18. non-small-cell lung cancer patients with high KLK13 expression at the mRNA or protein level had lower overall survival PMID:18627302
19. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. PMID:19707197

Show More

Hide All

HGNC: 6361

UNIGENE: Hs.165296

KEGG: hsa:26085

STRING: 9606.ENSP00000470555

OMIM: 605505